Treatment of Monolateral Legg-Calvé-Perthes Disease with Autologous Bone Marrow Mononuclear Cells in 32 Dogs

Alberto Maria Crovace1 Luca Lacitignola2☆ Francesco Staffieri2 Edda Francioso2 Giacomo Rossi3 Antonio Crovace2

1IRCSS Saverio De Bellis, Castellana Grotte (Bari), Italy
2Dipartimento dell’Emergenze e trapianti di Organo, Università degli Studi di Bari, sez Cliniche veterinarie e p.a., Bari, Puglia, Italy
3University of Camerino School of Bioscience and Veterinary Medicine, Camerino, Marche, Italy

Address for correspondence Luca Lacitignola, DVM, PhD, Dipartimento dell’Emergenze e trapianti di Organo, Università degli Studi di Bari, sez Cliniche veterinarie e p.a., Bari 70010, Puglia, Italy (e-mail: luca.lacitignola@uniba.it).

Objectives

In the present study, we report our results of the use of autologous bone marrow mononuclear cells (BMMCs) as a minimally invasive treatment for Legg-Calvé-Perthes in dogs.

Study Design

In accordance with Ljunggren’s scale, inclusion criteria were determined by clinical condition and radiographic features of the disease, resulting in 32 dogs enrolled in this retrospective study from 2007 to 2019. Bone marrow was collected from each dog from the iliac crest and the mononuclear fraction was separated with density gradient centrifugation. The mean number of BMMCs was $104.7 \pm 46.5 \times 10^6$ cells. The mean BMMC colony-forming units were $71.6 \pm 51.9 \times 10^3$ cells/mL.

Cells were suspended in fibrin glue before BMMC administration and implanted via transcutaneous injection under computed tomography or radiographic guidance, using a Jamshidi needle inserted through the femoral head and neck.

Results

A progressive reduction of pain within 3 weeks after BMMC administration was observed in 28 patients, with gradually increased weight bearing on the affected limb. In four dogs, however, pain and lameness persisted and at 3 months post-BMMC injection, femoral head and neck resection was performed. Histological and immunohistochemical studies were done on samples from those four dogs, which showed evidence of formation of new cartilage and subchondral bone in the area where cells were implanted.

Clinical Significance

Based on these results, BMMC therapy may be considered as effective and minimally invasive treatment option for LCPD in dogs.

Introduction

Legg-Calvé-Perthes disease (LCPD) was first identified in children by Legg, Calvé and Perthes in 19101–3; in dogs, the disease was first described by Tutt in 1935.4 In canines, the average time of disease onset is at 7 months of age, with no gender differences. In 10 to 15% of cases, LCPD is bilateral; the incidence is 2.8 cases per 1000.5 Legg-Calvé-Perthes disease has well-defined clinical and radiologic characteristics, although the aetiology and pathogenesis have not yet been completely revealed. The pathological features of LCPD are typical for avascular necrosis of bone tissue, followed by attempts to revascularization and bony remodelling of the femoral head. The most recent epidemiologic hypothesis in LCPD involves the expression...
of a defect in endochondral ossification and considers the disease to be a type of osteochondritis.\textsuperscript{6}

Several treatment methods have been proposed in LCPD aimed at promoting blood supply, such as core decompression, or conservative approach such as physiotherapy to reduce pain, and femoral head and neck resection as treatment of choice.\textsuperscript{7,8}

Recently, many authors researching treatment options for avascular necrosis of the femoral head (ANFH) in humans have proposed the use of bone marrow (BM)\textsuperscript{9–11} and BM-derived cells.\textsuperscript{12–18} Bone marrow-derived cells have been employed in dogs, to verify their efficacy as a translational model for ANFH in humans.\textsuperscript{19,20} Several favourable biological characteristics make bone marrow mesenchymal stem cells (BMSCs), an ideal therapeutic agent for bone regeneration.\textsuperscript{21–24} The aim of this study was a retrospective evaluation of dogs with LCPD we treated with autologous bone marrow mononuclear cell (BMMC) implantation during the past 12 years.

**Materials and Methods**

**Population**

Clinical records of 32 dogs affected by monolateral LCPD and treated with BMMC implantation between 2007 and 2019 were included.

All treatments were performed according to the Italian guidelines on the use of stem cells for clinical applications in veterinary medicine (Gazzetta Ufficiale (Italy) serie generale n. 277 del 26/11/2013) and each dog owner provided informed consent.

**Clinical Examination**

In preoperative and postoperative evaluations, we considered hip pain during passive movement of the coxofemoral joint, the degree of lameness, gait and findings of radiologic and computed tomography (CT) examinations. The diagnosis of LCPD was based on the following clinical findings: monolateral hip pain, lameness and radiographic lesions graded 1 to 3 based on the Ljunggren scale.\textsuperscript{8} Cases of Ljunggren grade 4 and 5 were not included because of the severe modifications of the femoral head and neck.

**Bone Marrow Harvesting**

After sedation with acepromazine (0.02 mg/kg) and methadone (0.3 mg/kg), induction and maintenance of general anaesthesia were obtained with propofol (5 mg/kg). The hip region was prepared for aseptic surgery. Bone marrow was harvested from the iliac crest using an 18-gauge Jamshidi needle or, a 24-gauge epidural needle. Aspiration of bone marrow was performed using a 20 mL syringe containing heparin (2500 IU/20 mL) (\textendash Fig. 1). Ten mL of BM was considered as the minimum volume for the procedure. If this amount was not reached with a single site, then another harvesting was performed in the opposite iliac crest.

**Bone Marrow Processing and BMMC Isolation**

Bone marrow was diluted 1:1 in phosphate buffered saline (PBS), then layered 1:1 on Biocoll separation medium (Ficoll density gradient 1.077 g/mL; Biochrom, Berlin, Germany) and centrifuged at 2000 rpm × 30 minutes. The separated cells were counted using nuclear staining (0.1% methyl violet in 0.1 M citric acid). The cells were rinsed twice with PBS and then diluted in an adequate amount of fibrin glue (Tissucol; Baxter Spa, Rome, Italy).

To evaluate the capacity of the cells to form colony-forming unit fibroblasts (CFU-f), 100 \( \mu \)L of cells were seeded before and after density gradient centrifugation in two Petri dishes (100 mm diameter) in complete medium (Coon’s F-12 medium, 10% foetal bovine serum, 100 IU/mL penicillin and streptomycin, 5% of a 200 \( \mu \)M solution of L-glutamine; Biochrom), and incubated at 37°C in a humid 5% CO\textsubscript{2}/air (carbogen) atmosphere for 2 weeks, with the medium replaced twice a week. The cells were then washed with PBS, pH 7.2, fixed with 4% buffered formalin and stained with 1% methylene blue in borate buffer (10 mM, pH 8.8).

**BMMC Injection**

The dogs were re-anaesthetized using propofol (5 mg/kg). For injection of the BMMCs into the femoral head and neck, the BMMCs were suspended in 1 mL of fibrinogen. After injection of BMMCs + fibrinogen, 0.3 mL of thrombin was immediately injected using the same needle, to clot the suspension and avoid the backflow. This procedure was
conducted under radiographic imaging or CT guidance using an 18-gauge Jamshidi needle for insertion into the femoral head via an intertrochanteric injection or directly into the femoral head (Fig. 2).

Follow-Up
In the postoperative period, in each dog antibiotic medications were administered for 7 days (Amoxicillin/Clavulanic acid 25 mg/kg q 12h). Nonsteroidal anti-inflammatory drugs were avoided post-surgically to exclude any possible interference with the BMMC effect. Orthopaedic, radiographic and CT examinations were performed at 3 weeks and 3 months after the procedure in all cases. Long-term radiographic follow-up at 1, 2, 4 and 6 years was available in selected cases.

Histology, Histochemistry and Immunohistochemistry
Among the total number of dogs treated, four had persistent pain and lameness at 3 months after treatment, indicating the need for femoral head and neck ostectomy. In these cases, the femoral head and neck were harvested and fixed in 10% buffered formalin, and then decalcified in a solution of 10% ethylene-diamine-tetra-acetic acid in 0.1 M phosphate buffer, pH 7–8, for ~8 weeks, changing the solution once a week. Ethylene-diamine-tetra-acetic acid decalcification is optimal for proteoglycan preservation and is highly recommended for sections destined for immunohistochemistry (IHC). After paraffin inclusion, the same tissues were cut into 4-μm thick sections, placed on pre-treated slides (Bio-Optica, Milan, Italy) to promote adhesion, and dried overnight at 37°C.

To obtain controls, we retrieved paraffinized tissue samples from untreated dogs with LCPD who previously underwent femoral head and neck resections; for this analysis, femoral head-neck samples from three male dogs (a 7-month-old Papillon and two Yorkshire Terriers aged 9 and 10.5 months) with a history of severe clinical signs of pain and lameness were selected from the Veterinary Pathology Unit archives, University of Camerino. These samples had been obtained immediately following a surgical procedure in dogs that presented for elective surgery (femoral neck resection controls, FNRC).

Eight non-consecutive sections, obtained at 100-μm intervals, were measured per each femoral head (in both the histological study group [HSG] and FNRC groups). The following parameters were evaluated at the central level of the femoral head: cartilage thickness, proteoglycan content ratio based on safranin O staining intensities (PC), chondrocyte density (CD) and subchondral bone staining intensities (BI). The degree of user interaction varied from manually tracing objects to nearly complete computer automation. For cartilage parameters, particularly evaluation of the new cartilage regeneration process inside the femoral head, four sections were stained with safranin O and counter-stained with light green. For bone parameters, four additional non-consecutive sections were stained using Herovici polychrome dye, to evaluate the different tissues and for pre-collagen and collagen differentiation. All slides were stained with haematoxylin and eosin (H&E) for general morphological evaluation. Finally, the presence of probably derived BMMCs was immunohistochemically evaluated using mouse monoclonal antibody anti-CD34 (Clone BL-35C; Zymed Inc., San Francisco, California, United States). Specific primary antibody substituted with Tris buffered saline or non-immune serum was used as the negative control in immunohistochemical techniques. For IHC tests, sections were treated as described elsewhere. Immunohistochemical evaluation was made for the presence of CD34+ cell expression in cartilaginous areas and interspersed or localized in perivascular fashion throughout the damaged area of the femoral head, assessed at 100× magnification.
A score of 0 (absence of antigen expression), 1 (weak and
spotted antigen expression), 2 (weak but diffuse antigen
expression throughout the entire specimen) and 3 (diffuse
and strong antigen expression) was assigned in a semiqua-
titative evaluation of the immunohistochemical reaction. Com-
puted tomography, expressed in micrometres, was measured
at 20× magnification, using an image-analysis system con-
sisting of a light microscope (Carl Zeiss, Jena, Germany)
attached to a Javelin JE3462 high-resolution camera and a
personal computer equipped with a Coreco-Oculus OCT-TCX
frame grabber and high-resolution monitor. Computerized
colour-image analysis was performed using Image-Pro Plus
software (Media Cybernetics; Rockville, Maryland, United
States). After manual delimitation of the cartilage between
two reference marks (1 and 2) and the subchondral bone, the
resulting area of cartilage was automatically segmented (using
a threshold for black and white extraction with a green image),
and the CT was calculated as the mean length of all the
segments generated from each pixel situated on the border
of the corresponding area of the cartilage.

The PC was approximated by quantification of the safranin
O staining intensity (SOI) of the histological section. The area
of measurement was centrally positioned between reference
marks 1 and 2, and segmentation of the cartilage was auto-
matically generated for measurement of the CT. The intensity
was evaluated in the superficial (S) and deep (D) zones of the
cartilage with manual delimitation at the upper margin of the
D zone. Intensity was automatically measured as the optical
density calculated on a greyscale obtained using the red
component of the light passing through the section. To mini-
mize the differences in safranin O staining between the
sections and because PC varies differentially during experi-
mental optics acquisition in the S and D zones, the following
ratio was calculated: SOI in the S zone divided by SOI in the D
zone; this justifies expression of the PC as a ratio.

The CD was evaluated at 200× magnification with manual
counting of the cells divided by automatic calculation of the
cartilage surface. Chondrocyte density is expressed in num-
ber of cells/mm². Cartilage parameters (CT and CD) were
successively measured in each of the four non-consecutive
sections stained with safranin O, and the bone parameter (BI)
was measured in the four non-consecutive sections stained
with Herovici polychrome dye and evaluated in terms of O.D.
of different red colour variations. Finally, for CD34+ cells, the
count was performed in four randomly selected cartilagi-
nous fields, as follows: the number of IHC-positive cells was
expressed as the number of stained cells in 100 randomly
counted cells, as a percentage. For each dog, the data of each
parameter were the mean of the four measurements
obtained from the four sections. All sections were read
blindly.

Statistical Analysis
Using MedCalc 14.8.1, parametric data were evaluated for
normal distribution, and a comparison between the HSG and
FNRC groups was performed with a one-way analysis of
variance test. Nonparametric data were compared with a
Kruskal–Wallis test. Significance was set at p < 0.05.

Results
Study Population
In this retrospective study, we enrolled the following 32 dogs
of different breeds who were affected by monolateral LCPD:
Poodle (n = 6), Pinscher (n = 6), Jack Russell Terrier (n = 4),
Yorkshire Terrier (n = 3), Pomeranian (n = 2), Fox Terrier
(n = 2), Scottish Terrier (N = 1), Papillon (n = 1), Russian
Toy (n = 1), Chihuahua (n = 1) and mixed breed (n = 5); males
(n = 23) and females (n = 9), average age 9.5 ± 2.5 months,
average weight 4.7 ± 1.3 kg.

Dogs presented with different degrees of lameness, myoa-
rophy and shortening of the affected legs. Physical examination
showed hip pain during passive movement of the coxofemoral
joint, particularly during leg abduction. Radiographic and CT
examinations confirmed the diagnosis and allowed staging in
LCPD grade 1 (n = 3), grade 2 (n = 11) and grade 3 (n = 18)
according to the Ljunggren scale (Figs. 3 and 4).

No major complications or infections were seen neither after
bone marrow harvesting nor after intra-osseous injection of
BMMCs. For the latter, laterolateral X-rays or CT guidance were
helpful to allow accurate injection into the necrotic and peri-
necrotic area and to avoid the potential risk of damage to the
retinacular vascular blood supply of the femoral head; in fact,
the dorsal and ventral retinacular artery remained throughout
unaffected by trajectory of the needle. We harvested a mean of
14.3 ± 5.2 mL bone marrow. The number of BMMCs obtained
after Ficoll separation was 104.7 ± 46.5 × 10⁶/mL. The total
CFUs from bone marrow were 71.6 ± 51.9 × 10⁶/mL.

Follow-Up
A progressive and clear reduction of pain upon passive abduc-
tion and weight bearing and an improvement in gait was
observed in 28 (87.5%) of the treated dogs within 3 weeks.

In all dogs, at 3 weeks, radiography did not show any
radiographic changes, as compared with preoperative exami-
nations. In four of the treated dogs (12.5%), we observed
persistent hip pain and lameness.

After 3 months, the 28 improved dogs showed no signs of
pain and normal gait. Radiographic examination at this
follow-up showed an increase in sclerosis of the femoral
head and a reduction in radiolucent zones with only mild
periarticular changes. However, radiography and CT scan
also revealed persistent collapse of the femoral head and
incongruence of the coxofemoral joint (Fig. 5). The long-
term follow-ups on selected cases revealed normal gait
despite the radiographic persistence of the articular collapse
and joint incongruence (Fig. 6) in 4 of the 32 dogs, pain and
lameness persisted; therefore, femoral head and neck resec-
tion was performed.

Histology, Histochemistry and IHC
Morphological examination of the femoral head and neck of
control dogs not subjected to stem cell therapy, revealed the
presence of large erosive–necrotic processes, particularly at
the level of the neck and in some areas of the head (Fig. 7A),
associated with a complete lack of safranin O staining, indicat-
ing a loss of proteoglycan content in the articular cartilage and
Fig. 3 Bone marrow mononuclear cell (BMMC) injection. (A) BMMCs injected in the femoral head and neck with a Jamshidi needle. (B) X-ray image before BMMC injection. (C) Injection of BMMCs mixed with contrast medium. In this specific case, the contrast medium was added to cells to detect the distribution of injected suspension in the necrotic areas.

Fig. 4 Representative radiologic images show persistence of collapsed femoral head and incongruence of coxofemoral joint. (A) Before treatment and (B) 90 days after treatment.

Fig. 5 Representative computed tomography images of a case (A) before treatment and (B) 90 days after treatment.
Fig. 6 Legg-Calvé-Perthes disease representative X-rays in ventrodorsal view before treatment (upper row series) and at different follow-up times (bottom row series). In particular (A) Grade III case with severe necrotic area of the femoral head. (A1) Follow-up at 6 years post bone marrow mononuclear cell (BMMC) treatment. Note sclerotic femoral head and neck with moderate articular modification. (B) Grade II case with small necrotic foci in the femoral head and neck. (B1) Follow-up at 2.5 years post BMMC treatment. Note the sclerosis of femoral head, shortening and widening of the neck and a good joint congruency. (C) Grade III case with severe modification of femoral head and joint incongruence. (C1) Follow-up at 1 year after treatment; note sclerosis with severe modification of the femoral head and neck shape and severe articular incongruence. (D) Grade III case with necrotic areas in the dorsal aspect of femoral head, with incongruent joint. (D1) Follow-up at 4 years after BMMC treatment. Sclerosis of the femoral head and neck with modification of the dorsal neck, moderate articular incongruence. (E) Grade II case with small necrotic foci and articular modification and incongruence. (E1) Follow-up at 2 years after BMMC treatment. Sclerosis of femoral head and large modification of neck with severe incongruence of articular surfaces.

Fig. 7 Consecutive histological sections of femoral head and neck from untreated control dogs (femoral neck resection controls [A–C]), and from bone marrow mononuclear cell (BMMC)-injected dogs (histological study group, HSG [D–I]), at 3 months after post-treatment. The femoral head is partially eroded and a large erosive–necrotic process is present on the neck (arrowheads) of a control dog, as revealed with haematoxylin and eosin (H&E) stain (A). In the same areas, a complete loss of proteoglycan content in the articular cartilage (arrowheads) and growth plate (normally stained in orange) is observed with safranin O stain (B). At the same level, Herovici polychrome stain reveals diffuse secondary ossification (bright red stain, arrowheads) and a notable lack of newly formed collagen or neo-angiogenesis or signs of regeneration in the same area (C). Note the presence of necrotic merged-colour-stained tissue at the end of the femoral neck. By contrast, the femoral head and neck of an HSG dog shows new fibrocartilage deposition in BMMC-treated and inflamed areas (arrowheads) in H&E-stained sections (D and G) and new nuclei of cartilage formation (G, arrows); at the same level, safranin O stain reveals proteoglycan synthesis and deposition (arrowheads, E and small arrowheads, H). Note intense orange safranin O staining of the new nuclei of chondrification (arrows, H). Finally, Herovici polychrome stain demonstrates large extracellular matrix deposition in the area of BMMC injection, composed of immature collagen, most likely corresponding to collagen type III (light-blue stained; F and D, arrowheads) and associated with neo-angiogenesis. H&E; safranin O; Herovici polychrome stain. Scale bar = 3.5 mm (A–F); scale bar = 7 mm (G–I).
growth plate (► Fig. 7B). In the head and neck of all controls, Herovici polychrome stain evidenced diffuse secondary ossification (► Fig. 7C, arrowheads) and a notable lack of newly formed collagen, lack of neo-angiogenesis and of signs of regeneration. Morphological and histochemical staining was performed on the HSG group that had not clinically recovered by 3 months post-treatment; evidence was found of an inflammatory process and new fibrocartilage deposition in the BMMC-injected area (► Fig. 7D and 7G). In particular, nuclei of cartilage formation (► Fig. 7G, arrows) and proteoglycan synthesis and deposition (arrow heads, ► Fig. 7E) were stained orange with safranin O. In HSG dogs, Herovici polychrome staining revealed large areas of extracellular matrix deposition around the point of BMMC injection (► Fig. 7F and 7D, arrow heads), associated with neoangiogenesis. Quantification of CD34+ cells in histological sections of the femoral head and neck from HSG group and control FNRC animals revealed a high number of CD34+ cells, mainly aggregated around capillaries in areas of new fibrocartilage deposition (► Fig. 8A insert). Computed tomography PC, CD and BI were compared between the group HSG and control FNRC group. All analysed parameters are summarized in Table 1 and ► Fig. 9. In the HSG, the CT, PC, CD and BI were significantly higher than the FNRC group. CD34+ cells were only found in stem cell-injected femoral heads and were completely absent in controls (► Fig. 8A).

**Discussion**

The aim of this retrospective study was to evaluate the use of BMMMCs as a minimally invasive treatment for LCPD in dogs. The results showed that this technique gives good results in terms of swift recovery from pain and also leads to gradually increasing weight bearing on the affected limb, up to a complete remission of clinical signs at 3 months post-stem cell injection. Moreover, our data show that in case of failure of the BMMMCs treatment (12.5%), dogs can still be safely treated with the classical femoral head and neck excision.

The clinical effectiveness of the method described in this study has been shown previously in human medicine, but the role of transplanted cells remains unclear. Our histological and IHC findings showed an increased articular cartilage and subchondral bone thickening, with a marked neoangiogenesis in treated samples, but complete absence thereof in the control group. Moreover, the presence of CD34+ cells, a marker found in bone marrow mononuclear cell-treated femoral heads and necks obtained after ostectomy in dogs with Legg-Calvé-Perthes disease, could have been responsible for the regenerative effect, directly or indirectly through cell recruitment and chemotaxis, as found in other mesenchymal tissues. It has been documented that BMMMCs secrete a wide spectrum of factors with immunomodulatory, anti-inflammatory, antiapoptotic, proangiogenic, proliferative or chemoattractive capacities. Pain improvement is probably owing to the anti-inflammatory capacity of stromal cells. Indeed, mesenchymal stromal cells have therapeutic potential for regenerative and anti-inflammatory therapy. Currently, several soluble factors that are either produced constitutively by BMMMCs or as the result of cross-talk with target immune cells, have been attributed to the immunomodulatory properties of BMMMCs.

**Table 1** Mean and standard deviation for cartilage thickness, proteoglycan content ratio based on safranin O staining intensities, chondrocyte density and subchondral bone staining intensities. Histological study group (consisting of bone marrow mononuclear cell-treated femoral heads and necks) showed significantly higher parameters than femoral neck resection controls (consisting of untreated femoral heads and necks obtained after ostectomy in dogs with Legg-Calvé-Perthes disease)

<table>
<thead>
<tr>
<th></th>
<th>CT</th>
<th>PC</th>
<th>CD</th>
<th>BI</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>FNRC</td>
<td>874.83</td>
<td>0.38</td>
<td>409.08</td>
<td>0.25</td>
<td>Mean</td>
</tr>
<tr>
<td>HSG</td>
<td>1414.00</td>
<td>0.53</td>
<td>747.06</td>
<td>0.54</td>
<td>Mean</td>
</tr>
<tr>
<td></td>
<td>208.48</td>
<td>0.07</td>
<td>121.39</td>
<td>0.09</td>
<td>SD</td>
</tr>
</tbody>
</table>

Abbreviations: BI, subchondral bone staining intensities; CD, chondrocyte density; CT, computed tomography; PC, proteoglycan content ratio based on safranin O staining intensities.

Note: Significance level $p < 0.05$.  

![Fig. 8](image-url) **Fig. 8** Representative images for immunohistochemical quantification of CD34+ cells in histological sections of the femoral head and neck from bone marrow mononuclear cell (BMMC)-injected dogs (histological study group) (► Fig. 8A) 3 months after treatment, in comparison with untreated control dogs (bone marrow mononuclear cell) (► Fig. 8B). A high number of CD34+ cells were only observed in sections from BMMC-injected dogs. Cells were mainly aggregated around capillaries (► Fig. 8A insert). Immunohistochemistry avidin-biotin Complex method, Meyer haematoxylin counterstain. Scale bar = 700 μm.
The amount of the injected BMMCs was very variable among our patients \(104.7 \pm 46.5 \times 10^6 / \text{mL}\), since the technique used to obtain the cells (for density gradient centrifugation) is depending on several factors including the original quality of harvested bone marrow, its volume and patient-related individual factors. Although some authors suggest that there is a direct correlation between the number of implanted cells and the treatment efficacy, at the moment, a clear reference target number is not available and the current literature suggests using the largest number of cells available.

Our good clinical results also seem related to increased precocious bone sclerosis, which is normally the last outcome of the disease, proven by radiographic and CT findings of persistent collapse of the femoral head and incongruence of the coxofemoral joint. Considering the minimally invasive and conservative approach of the proposed treatment, we suppose that a re-injection of the BMMCs could be an option in dogs not responding to the first treatment and/or with a recurrence of the symptoms. Further studies are required to confirm this hypothesis.

It has been considered that the reason for insufficient substitution in bone remodelling after osteonecrosis in the femoral head may be the small number of progenitor cells present in the femoral head. Others suggested that the effectiveness of bone marrow cells may be related to the availability of stem cells endowed with osteogenic properties in the femoral head, which increase after bone marrow implantation. Another possible explanation for the therapeutic effect of bone marrow implantation is that injected marrow stromal cells secrete angiogenic cytokines, resulting in increased angiogenesis and subsequent improvement in osteogenesis. Hernigou and colleagues stated that BMMCs can elicit the formation of new blood vessels via the presence of endothelial cell progenitors or haemangioblasts. This may be owing to both the supply of progenitor cells and to angiogenic cytokines produced by bone marrow cells. Endothelial progenitors can actively engage in angiogenesis in tissue devoid of vessels and in neo-angiogenesis from pre-existing capillaries via the angiopoietin-1/Tie2 pathway. In addition, local ischaemia that activates HIF1A signalling and mobilization of circulating progenitors via the SDF1-dependent pathway may provide permanent stimuli for blood vessel repair, as well as a supply of new cells for bone regeneration with chemotaxis or differentiated or undifferentiated resident cells for functional tissue restoration.

In a study on cartilage repair using freshly isolated BMMCs as controls, Jiang and colleagues stated that cells obtained from in vitro culture and expansion are not recommended for cell-based therapy and that fresh BMMCs are the best choice. The absence of a clinical control group can be considered a limitation of this study.

The present results confirmed clinically what has already shown in experimental models on dogs. Indeed, Yan and colleagues investigated the survival and differentiation of MSCs transplanted in skeletally mature mongrels in which osteonecrosis of the femoral head was surgically induced; patients were treated with either saline (control) or autologous BMSC transplantation. These previous results demonstrate that transplanted autologous BMSCs can survive, proliferate and differentiate into osteoblasts directly, which contributes to acceleration of the repair process. Hang and colleagues and Liu and colleagues evaluated the efficacy of vascular endothelial growth factor 165 in transgenic BMSCs for the repair of early-stage osteonecrosis of the femoral head in mature mongrel dogs. After core decompression, transgenic and non-transgenic...
autologous BMSCs were implanted and therapeutic efficacy was obtained, with new bone formation and neovascularization in the femoral head confirmed in collateral examinations. Jin and colleagues investigated the effects of autologous BMSCs administered via arterial perfusion on vascular repair and angiogenesis in an experimental model of osteonecrosis of the femoral head in dogs. Three weeks after establishment of ischaemia in the femoral head, a good therapeutic effect was obtained, with BMSCs promoting vascular repair and angiogenesis. In conclusion, on the basis of our results, we consider the technique described as minimally invasive, with no disadvantages, and that implantation of autologous bone marrow cells can be a valid alternative approach to the classical surgical treatment of LCPD with femoral head and neck excision; in case of non-response to cell treatment, surgery may still be performed successfully.

Conflict of Interest
None declared.

References
4 Tutt J. Tuberculosis of the hip joint in a cairn terrier. Vet Rec 1935; (47):428–431
12 Cabrolier J, Molina M. [Is instillation of bone marrow stem cells at the time of core decompression useful for osteonecrosis of the femoral head?] Medwave 2016;16(02, Suppl 1):e6406
28 Camplejohn KL, Allard SA. Limitations of safranin ‘O’ staining in proteoglycan-depleted cartilage demonstrated with monoclonal antibodies. Histochemistry 1988;89(02):185–188
30 El-Jawhari JJ, El-Sherbiny YM, Jones EA, McGonagle D. Mesenchymal stem cells, autoimmunity and rheumatoid arthritis. QJM 2014;107(07):505–514


